Skip to main content Accessibility help
×
Hostname: page-component-8448b6f56d-m8qmq Total loading time: 0 Render date: 2024-04-19T20:34:47.479Z Has data issue: false hasContentIssue false

148 - Vilazodone

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Viibryd

Generic?

• No

Class

• Selective serotonin reuptake inhibitor (SSRI)

Commonly Prescribed for

(FDA approved in bold)

Major depressive disorder

• Generalized anxiety disorder

• Chronic pain

How the Drug Works

• It blocks the serotonin transporter (SERT) (Ki = 0.1 nM) and is a presynaptic 5-HT1A partial agonist

How Long Until It Works

• 2 weeks to 2 months for full effect

If It Works

• Continue to use and monitor for AEs

If It Doesn't Work

• Increase to highest tolerated dose. Consider adding a second agent or changing to another one

Best Augmenting Combos for Partial Response or Treatment-Resistance

• For some patients, low-dose polytherapy with 2 or more drugs may be better tolerated and more effective than high-dose monotherapy

Tests

• None available

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• By increasing serotonin on non-therapeutic responsive receptors throughout the body. Most AEs are dose- and time-dependent

Notable AEs

• Incidence ≥ 5%: insomnia, nausea, vomiting, diarrhea

Life-Threatening or Dangerous AEs

• Serotonin syndrome

• Rare activation of mania or suicidal ideation, especially during the initial few months

• Angle-closure glaucoma

• Rare worsening of existing seizure disorders

• Rare hyponatremia and abnormal bleeding

Weight Gain

• Unusual

Sedation

• Not unusual

What to Do About AEs

• For minor AEs, lower dose, titrate more slowly, or switch to another agent. For serious AEs, lower dose and consider stopping, taper to avoid withdrawal

Best Augmenting Agents to Reduce AEs

• Cyproheptadine can be used for serotonin syndrome by blocking 5-HT receptors and SERT

DOSING AND USE

Usual Dosage Range

• 40mg once daily

Dosage Forms

• Tablet: 10, 20, 40mg

How to Dose

• Initial 10mg daily for 7 days, followed by 20mg daily for 7 days, then increase to 40mg daily

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 546 - 548
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Vilazodone
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.149
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Vilazodone
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.149
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Vilazodone
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.149
Available formats
×